目的 觀察注射用烏司他丁聯(lián)合地塞米松磷酸鈉注射液治療急性呼吸窘迫綜合征的臨床效果。方法 選取2016年3月—2017年3月成都市第二人民醫(yī)院收治的急性呼吸窘迫綜合征患者96例為研究的對(duì)象，將所有患者隨機(jī)分為對(duì)照組和治療組，每組各48例。對(duì)照組靜脈滴注地塞米松磷酸鈉注射液，5 mg加入到5%葡萄糖注射液250 mL中，2次/d。治療組在對(duì)照組的基礎(chǔ)上靜脈滴注注射用烏司他丁，5萬(wàn)單位加入到5%葡萄糖注射液250 mL中，2次/d。兩組患者均連續(xù)治療2周。觀察兩組的臨床療效，比較兩組的住院時(shí)間、住重癥監(jiān)護(hù)室（ICU）時(shí)間、病死率和肺功能指標(biāo)。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為77.1%、95.8%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，治療組住院時(shí)間、住ICU時(shí)間、病死率均低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組氧合指數(shù)均顯著升高，治療組呼吸頻率顯著降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 注射用烏司他丁聯(lián)合地塞米松磷酸鈉注射液治療急性呼吸窘迫綜合征具有較好的臨床療效，可以改善肺功能，縮短住院時(shí)間和住ICU時(shí)間，降低病死率，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Ulinastatin for injection combined with Dexamethasone Sodium Phosphate Injection in treatment of acute respiratory distress syndrome. Methods Patients (96 cases) with acute respiratory distress syndrome in Chengdu Second People's Hospital from March 2016 to March 2017 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were iv administered with Dexamethasone Sodium Phosphate Injection, 5 mg added into 5% glucose solution 250 mL, twice daily. Patients in the treatment group were iv administered with Ulinastatin for injection on the basis of the control group, 50 000 units added into 5% glucose solution 250 mL, twice daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and hospitalization time, ICU stay time, fatality rate, and pulmonary function indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.1% and 95.8%, respectively, and there was difference between two groups (P < 0.05). After treatment, hospitalization time, ICU stay time, and fatality rate in the treatment group were lower than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the oxygenation indexes in two groups were significantly increased, but the respiratory frequency in the treatment group were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Ulinastatin for injection combined with Dexamethasone Sodium Phosphate Injection has clinical curative effect in treatment of acute respiratory distress syndrome, can improve pulmonary function, shorten hospitalization time and ICU stay time, reduce fatality rate, which has a certain clinical application value.